This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of VG081821AC Tablets in Patients With Early to Mid-stage Parkinson's Disease | MicrobiomeTrials
← Back to trials NCT07725562
Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of VG081821AC Tablets in Patients With Early to Mid-stage Parkinson's Disease Recruiting PHASE2, PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-17Est. Completion: 2027-10-01
Enrollment target: 152 participantsLocations Xuanwu Hospital of Capital Medical University, Beijing, China Other microbiome trials you might be interested in Idiopathic Parkinson´s Disease Parkinson's Disease
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be i…
Tucson, United States Est. completion Sep 2027
Head and Neck Neoplasms
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in c…
La Jolla, United States Est. completion Jul 25, 2024
Carcinoma, Non-Small-Cell Lung
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-…
Gilbert, United States Est. completion May 16, 2033